| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/06/2006 | WO2006070348A1 PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-κB ACTIVITY |
| 07/06/2006 | WO2006070325A2 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists |
| 07/06/2006 | WO2006070288A2 Aerosol generator |
| 07/06/2006 | WO2006070284A1 Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors |
| 07/06/2006 | WO2006070276A1 Process for preparing perindopril erbumine |
| 07/06/2006 | WO2006070275A1 Process for obtaining levofloxacin free from salts |
| 07/06/2006 | WO2006070248A1 Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine |
| 07/06/2006 | WO2006070208A1 Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists |
| 07/06/2006 | WO2006070202A1 Pyrazole derivatives having kinase modulating activity |
| 07/06/2006 | WO2006070198A1 Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| 07/06/2006 | WO2006070195A1 Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
| 07/06/2006 | WO2006070192A1 Thiazole and isothiazole derivatives that modulate the acivity of cdk, gsk and aurora kynases |
| 07/06/2006 | WO2006070129A1 Injectable or orally deliverable formulations of azetidine derivatives |
| 07/06/2006 | WO2006070106A1 N-[(4, 5-diphenyl-3-alkyl-2-thienyl) methyl] amine (amide, sulfonamide, carbamate and urea) derivatives as cannabinoid cb1 receptor antagonists |
| 07/06/2006 | WO2006070093A1 Composition comprising solubilized adapalene with cyclodextrins |
| 07/06/2006 | WO2006070022A2 Medicaments containing selenium for the treatment of endothelial vascular diseases |
| 07/06/2006 | WO2006070012A1 Agents useful in treating inflammatory bowel disease |
| 07/06/2006 | WO2006070004A1 Compounds useful in the treatment of hiv |
| 07/06/2006 | WO2006070001A1 Substituted indole ligands for the orl-1 receptor |
| 07/06/2006 | WO2006069998A2 Glycopyrrolate in cosmetic preparations |
| 07/06/2006 | WO2006069993A1 Arylpiperazine derivatives and use thereof as 5-ht1a receptor ligands |
| 07/06/2006 | WO2006069946A1 Substituted pyrrolidinones having an antithrombotic effect, the production thereof and their use as medicaments |
| 07/06/2006 | WO2006069938A1 Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it |
| 07/06/2006 | WO2006069920A1 Fast release dosage forms for antibiotics |
| 07/06/2006 | WO2006069809A1 Substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their preparation and use in medicaments |
| 07/06/2006 | WO2006069808A2 Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| 07/06/2006 | WO2006069807A1 Substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| 07/06/2006 | WO2006069806A1 Pharmaceutical composition comprinsing a 2,5-dihydroxybenzenesulfonic compounds, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor |
| 07/06/2006 | WO2006069788A1 Organic compounds |
| 07/06/2006 | WO2006069787A1 Decaline-derived compounds as pharmaceutically active agents |
| 07/06/2006 | WO2006069776A1 5-ht7 receptor antagonists |
| 07/06/2006 | WO2006069775A1 5-ht7 receptor antagonists |
| 07/06/2006 | WO2006069754A1 Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| 07/06/2006 | WO2006069740A1 2, 5 and 2, 6-disubstituted benzazole analogues useful as protein kinase inhibitors |
| 07/06/2006 | WO2006069705A1 Directly pressed indapamide tablets with delayed release of the active substance |
| 07/06/2006 | WO2006069678A1 Conjugates of metal complex hydroxypyridin derivatives and biomolecules and the use thereof for producing agents used in nmr diagnosis |
| 07/06/2006 | WO2006069668A1 Method for producing a raw oil from mixtures of micro-organisms and plants, oil produced according to said method and specific uses of the thus produced oil and, optionally, additional refined oil |
| 07/06/2006 | WO2006069578A1 Hyaluronic acid linked with a polymer of an alpha hydroxy acid |
| 07/06/2006 | WO2006069542A1 Self-assembly luminescent conductive nano-drug crystal and its ultra-thin film and its preparation |
| 07/06/2006 | WO2006069533A1 Desmosdumotins, their manufactures and use as antitumor and anti-aids agent |
| 07/06/2006 | WO2006069525A1 Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof |
| 07/06/2006 | WO2006069519A1 Solid dispersion of glibenclamide, its oral composition and methods |
| 07/06/2006 | WO2006069512A1 Methods for preparing dehydrocavidine, dehydroapocavidine or their composition, their use and medicinal composition containing them |
| 07/06/2006 | WO2006069466A1 Series of triterpenoid ptp1b inhibitors and their preparing method and use |
| 07/06/2006 | WO2006069452A1 Use of a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan for producing an agent for treating articular pains and method for applying said agent |
| 07/06/2006 | WO2006069451A1 Use of resiniferatoxin (rtx) for producing an agent for treating joint pains and method for applying said agent |
| 07/06/2006 | WO2006069441A1 Dipyrrole compounds, compositions, and methods for treating cancer or viral diseases |
| 07/06/2006 | WO2006069422A1 Method and means for improving bowel health |
| 07/06/2006 | WO2006069419A1 Nanoparticle composition and methods for synthesis thereof |
| 07/06/2006 | WO2006058059A3 Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject |
| 07/06/2006 | WO2006057900A3 17,20(z)-dehydro vitamin d analogs and their uses |
| 07/06/2006 | WO2006057899A3 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses |
| 07/06/2006 | WO2006055578A3 Asymmetric synthesis of (-)-agelastatin a |
| 07/06/2006 | WO2006053784A3 1,7-naphthyridines as pde4 inhibitors |
| 07/06/2006 | WO2006053274A3 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| 07/06/2006 | WO2006053227A3 Il-12 modulatory compounds |
| 07/06/2006 | WO2006052922A3 Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds |
| 07/06/2006 | WO2006052921A3 Cyclodextrin solubilizers for liquid and semi-solid formulations |
| 07/06/2006 | WO2006052893A3 Substituted pyrrolidone compounds as ep4 agonists |
| 07/06/2006 | WO2006052568A3 Tgf-beta inhibitors |
| 07/06/2006 | WO2006051374A3 Arylpiperazines useful as adrenergic receptor antagonists |
| 07/06/2006 | WO2006050511A8 Butyrophenomenes and sigma-1 receptor antagonists protect against oxidatives-stress |
| 07/06/2006 | WO2006050389A3 Pyridazine compounds, compositions and methods |
| 07/06/2006 | WO2006050314A3 Once a day formulation for phosphate binders |
| 07/06/2006 | WO2006050165A3 Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| 07/06/2006 | WO2006048560A3 Novel pharmaceutical compositions and the uses thereof for controlling the different forms of addiction to drugs |
| 07/06/2006 | WO2006047590A3 Compositions and treatments of bacterial vaginosis |
| 07/06/2006 | WO2006047514A3 Daph analogs and inhibition of protein aggregation |
| 07/06/2006 | WO2006047415A3 FACTOR Xa COMPOUNDS |
| 07/06/2006 | WO2006047251A3 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission |
| 07/06/2006 | WO2006046123A3 Conjugates with anti-inflammatory activity |
| 07/06/2006 | WO2006046039A3 Tetracyclic indole derivatives as antiviral agents |
| 07/06/2006 | WO2006046030A3 Tetracyclic indole derivatives as antiviral agents |
| 07/06/2006 | WO2006044933A3 Compositions and methods for disruption of brca2-rad51 interaction |
| 07/06/2006 | WO2006044856A3 Use of a2a adenosine receptor agonists |
| 07/06/2006 | WO2006044505A3 Compounds for nonsense suppression, and methods for their use |
| 07/06/2006 | WO2006044503A3 Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases |
| 07/06/2006 | WO2006043846B1 Salt of montelukast with tert.-butylamine |
| 07/06/2006 | WO2006043036A3 Treatment of diabetes |
| 07/06/2006 | WO2006042105A3 Promotion of cell migration and axon regeneration in the cns |
| 07/06/2006 | WO2006041985A3 Thienopyridinone compounds and methods of treatment |
| 07/06/2006 | WO2006041797A3 Acyclic hydrazides as cannabinoid receptor modulators |
| 07/06/2006 | WO2006040643A3 Polymorphic forms of efavirenz and processes for their preparation |
| 07/06/2006 | WO2006039414A3 Treatment method |
| 07/06/2006 | WO2006039281A3 Skin cancer prevention method and product |
| 07/06/2006 | WO2006035286A3 Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof |
| 07/06/2006 | WO2006034489A3 C-aryl glucoside sglt2 inhibitors and method for their production |
| 07/06/2006 | WO2006034239A8 Antimicrobial mesoporous silica nanoparticles |
| 07/06/2006 | WO2006033006A3 Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor |
| 07/06/2006 | WO2006031614A3 Reduced toxicity methotrexate formulations and methods for using the same |
| 07/06/2006 | WO2006030303A8 Oral extended release dosage form comprising a high dose biguanide and a low dose sulfonylurea |
| 07/06/2006 | WO2006026536A3 Method of treatment of cancer using guanosine 3’, 5’ cyclic monophosphate (cyclic gmp) |
| 07/06/2006 | WO2006024479A3 Pharmaceutical multiparticulate compositions comprising mycophenolic acid or mycophenolate sodium and combination compositions with rapamycin |
| 07/06/2006 | WO2006023944A3 Pulmonary delivery of inhibitors of phosphodiesterase type 5 |
| 07/06/2006 | WO2006018727A3 Triazolopyridine compounds useful for the treatment of inflammation |
| 07/06/2006 | WO2006018682A3 Oxazolidinone derivatives as antimicrobials |
| 07/06/2006 | WO2006017698A3 Novel statin pharmaceutical compositions and related methods of treatment |
| 07/06/2006 | WO2006017672A3 2, 8-disubstituted naphthyridine derivatives |
| 07/06/2006 | WO2006017215A3 Histone deacetylase inhibitors |
| 07/06/2006 | WO2006017109A3 Adhesive containing wound closure device and method |